Organization · Venture Capital
Palo Santo
Palo Santo is a U.S.-based venture capital firm focused on investing in early-stage companies innovating in mental health and wellness, particularly in the psychedelic healthcare sector.
Overview
What Palo Santo does
What Palo Santo is
Palo Santo is a U.S.-based venture capital firm focused on investing in early-stage companies innovating in mental health and wellness, particularly in the psychedelic healthcare sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- April 30, 2026
Official channels
Find Palo Santo elsewhere
Open the official website or a supported primary organization account.
Capability profile
Palo Santo as a funder
Investment thesis
Palo Santo believes mental health and neurological care are at an inflection point, with significant opportunities in novel CNS therapeutics and next-generation psychedelic therapies. The firm targets innovative solutions that can transform patient outcomes in mental health care.
Focus narrative
Palo Santo invests in early-stage companies that are developing solutions in mental health, wellness, and related fields. The firm emphasizes innovative approaches to mental health care, targeting sectors such as neuroscience, digital therapeutics, and addiction treatment.
Value beyond capital
Palo Santo adds value to its portfolio companies through specialized knowledge in neuroscience, clinical development, and regulatory pathways. The firm provides strategic guidance and support to help companies navigate the complexities of mental health therapeutics and achieve scalable patient access.
Terms and economics
- Typical check
- $500,000–$5,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Friends and Family · Accelerator
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 23
- Recorded notable exits
- Gilgamesh Pharmaceuticals and Transcend Therapeutics
Portfolio context
Mindstrong: A digital mental health platform that uses technology to improve mental health care. Tess: An AI-driven mental health platform that provides on-demand therapy. Ginger: A mental health support platform offering on-demand coaching and therapy. Gilgamesh Pharmaceuticals: Focused on psychedelic and neuropsychiatric therapeutics, recently acquired by AbbVie. Transcend Therapeutics: Developing MDMA-analogue treatments for psychiatric conditions, acquired by Otsuka. Reunion Neuroscience: Known for its FDA Breakthrough Therapy Designation for RE104.
Common questions
What to know about Palo Santo
Upseed classifies Palo Santo under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.